Biodesix (BDSX) News Today $0.71 -0.08 (-10.09%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$0.88 +0.17 (+23.28%) As of 03/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025March 4 at 6:15 AM | insidermonkey.comBiodesix, Inc. (BDSX) Q4 2024 Earnings Call TranscriptMarch 3 at 9:01 PM | seekingalpha.comBiodesix (NASDAQ:BDSX) Posts Earnings Results, Beats Estimates By $0.01 EPSBiodesix (NASDAQ:BDSX - Get Free Report) issued its earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%.March 3 at 4:34 PM | marketbeat.comBiodesix Announces Fourth Quarter and Fiscal Year 2024 ResultsMarch 3 at 4:01 PM | globenewswire.comBiodesix (BDSX) Expected to Announce Quarterly Earnings on MondayMarch 2 at 2:09 AM | americanbankingnews.comBiodesix (NASDAQ:BDSX) and First Choice Healthcare Solutions (OTCMKTS:FCHS) Critical ComparisonFebruary 27, 2025 | americanbankingnews.comBiodesix to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | globenewswire.comBiodesix (BDSX) Expected to Announce Earnings on MondayBiodesix (NASDAQ:BDSX) will be releasing earnings after the market closes on Monday, March 3. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=667161)February 24, 2025 | marketbeat.comBiodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025February 18, 2025 | globenewswire.comBiodesix, Inc. (NASDAQ:BDSX) Insider Sells $15,408.16 in StockFebruary 13, 2025 | insidertrades.comInsider Selling: Biodesix, Inc. (NASDAQ:BDSX) Insider Sells 16,748 Shares of StockBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) insider Gary Anthony Pestano sold 16,748 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $15,408.16. Following the sale, the insider now directly owns 156,008 shares of the company's stock, valued at approximately $143,527.36. This trade represents a 9.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.February 12, 2025 | marketbeat.comRobin Harper Cowie Sells 24,664 Shares of Biodesix, Inc. (NASDAQ:BDSX) StockBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) CFO Robin Harper Cowie sold 24,664 shares of Biodesix stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $22,690.88. Following the completion of the sale, the chief financial officer now owns 246,460 shares of the company's stock, valued at approximately $226,743.20. The trade was a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.February 12, 2025 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton Sells 83,660 SharesBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) CEO Scott Hutton sold 83,660 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares of the company's stock, valued at $645,791.24. This trade represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 12, 2025 | marketbeat.comShort Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 7.4%Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a significant drop in short interest in January. As of January 15th, there was short interest totalling 836,600 shares, a drop of 7.4% from the December 31st total of 903,100 shares. Based on an average trading volume of 420,900 shares, the short-interest ratio is presently 2.0 days.February 1, 2025 | marketbeat.comShort Interest in Biodesix, Inc. (NASDAQ:BDSX) Drops By 7.4%Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 836,600 shares, a decrease of 7.4% from the December 15th total of 903,100 shares. Based on an average daily volume of 420,900 shares, the short-interest ratio is presently 2.0 days.January 18, 2025 | marketbeat.comLake Street Sticks to Their Buy Rating for Biodesix (BDSX)January 10, 2025 | markets.businessinsider.comCraig-Hallum Gives a Buy Rating to Biodesix (BDSX)January 10, 2025 | markets.businessinsider.comBiodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)January 10, 2025 | globenewswire.comBiodesix Announces Publication of a New Nodify CDT® Clinical Validation StudyJanuary 7, 2025 | globenewswire.comShort Interest in Biodesix, Inc. (NASDAQ:BDSX) Expands By 44.7%Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 903,100 shares, an increase of 44.7% from the November 30th total of 624,200 shares. Based on an average daily trading volume, of 395,100 shares, the short-interest ratio is presently 2.3 days.December 28, 2024 | marketbeat.comWilmington Savings Fund Society FSB Takes Position in Biodesix, Inc. (NASDAQ:BDSX)Wilmington Savings Fund Society FSB acquired a new position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 6,095,034 shares of the company's stock, valued at approximately $10,849,00December 12, 2024 | marketbeat.comBiodesix, Inc. (BDSX)November 24, 2024 | finance.yahoo.comInsider Buys Additional US$234k In Biodesix StockNovember 23, 2024 | uk.finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Director Jack W. Schuler Acquires 200,000 SharesNovember 22, 2024 | insidertrades.comBiodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck Purchases 40,000 SharesNovember 7, 2024 | insidertrades.comBiodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | msn.comBiodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 4, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Buy" from AnalystsShares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokeragesNovember 3, 2024 | marketbeat.comBiodesix (NASDAQ:BDSX) Issues Earnings Results, Beats Expectations By $0.01 EPSBiodesix (NASDAQ:BDSX - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. The firm had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. During the same period last year, the firm posted ($0.12) earnings per share.November 2, 2024 | marketbeat.comBiodesix Reports Strong Q3 2024 Growth in DiagnosticsNovember 2, 2024 | markets.businessinsider.comBiodesix files to sell 62.2M shares of common stock for holdersNovember 1, 2024 | markets.businessinsider.comBiodesix: Poised for Recovery and Growth Amid Temporary SetbacksNovember 1, 2024 | markets.businessinsider.comBiodesix Announces Third Quarter 2024 Results and HighlightsNovember 1, 2024 | globenewswire.comCraig-Hallum Sticks to Its Buy Rating for Biodesix (BDSX)October 29, 2024 | markets.businessinsider.comBiodesix to Participate in Three Investor Conferences in NovemberOctober 29, 2024 | globenewswire.comBiodesix (BDSX) Set to Announce Quarterly Earnings on FridayBiodesix (NASDAQ:BDSX) will be releasing earnings before the market opens on Friday, November 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637164)October 25, 2024 | marketbeat.comBiodesix to Report Third Quarter 2024 Financial Results on November 1, 2024October 18, 2024 | businesswire.comBiodesix, Inc. (NASDAQ:BDSX) Short Interest Up 29.3% in SeptemberBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 419,700 shares, an increase of 29.3% from the September 15th total of 324,700 shares. Based on an average daily volume of 128,000 shares, the short-interest ratio is presently 3.3 days.October 13, 2024 | marketbeat.comBiodesix (NASDAQ:BDSX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comPerceptive Advisors LLC Takes $3.33 Million Position in Biodesix, Inc. (NASDAQ:BDSX)Perceptive Advisors LLC purchased a new position in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,173,880 shares of the company's stSeptember 30, 2024 | marketbeat.comFarallon Capital Management LLC Purchases New Stake in Biodesix, Inc. (NASDAQ:BDSX)Farallon Capital Management LLC purchased a new stake in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,878,175 shares of the company's stock, valued at approximately $2,874,000. FaraSeptember 24, 2024 | marketbeat.comCraig-Hallum Keeps Their Buy Rating on Biodesix (BDSX)September 21, 2024 | markets.businessinsider.comShort Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 15.6%Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 357,500 shares, a decrease of 15.6% from the August 15th total of 423,500 shares. Based on an average daily volume of 143,400 shares, the short-interest ratio is presently 2.5 days.September 16, 2024 | marketbeat.comScotiabank Initiates Coverage on Biodesix (NASDAQ:BDSX)Scotiabank assumed coverage on Biodesix in a research report on Monday. They issued a "sector outperform" rating on the stock.September 16, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of "Buy" from AnalystsBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target prSeptember 14, 2024 | marketbeat.comAIGH Capital Management LLC Purchases 2,458,727 Shares of Biodesix, Inc. (NASDAQ:BDSX)AIGH Capital Management LLC raised its stake in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 74.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,779,812 shares of the company's stock after acquiring an aSeptember 9, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Sees Significant Decrease in Short InterestBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a significant decline in short interest in August. As of August 15th, there was short interest totalling 423,500 shares, a decline of 5.9% from the July 31st total of 450,100 shares. Based on an average daily volume of 137,100 shares, the short-interest ratio is presently 3.1 days.September 2, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Given Average Rating of "Buy" by AnalystsBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) has been given an average rating of "Buy" by the six brokerages that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts tAugust 20, 2024 | marketbeat.comBiodesix, Inc. (NASDAQ:BDSX) Sees Large Decline in Short InterestBiodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 450,100 shares, a decrease of 11.2% from the July 15th total of 506,900 shares. Based on an average daily volume of 144,500 shares, the short-interest ratio is currently 3.1 days.August 17, 2024 | marketbeat.comBiodesix (NASDAQ:BDSX) Announces Earnings Results, Beats Estimates By $0.01 EPSBiodesix (NASDAQ:BDSX - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. Biodesix had a negative return on equity of 29,379.44% and a negative net margin of 85.80%. The company had revenue of $17.93 million for the quarter, compared to the consensus estimate of $16.05 million. During the same period last year, the business posted ($0.17) earnings per share.August 11, 2024 | marketbeat.com Get Biodesix News Delivered to You Automatically Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter. Email Address BDSX Media Mentions By Week BDSX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDSX News Sentiment▼0.570.70▲Average Medical News Sentiment BDSX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDSX Articles This Week▼91▲BDSX Articles Average Week Get Biodesix News Delivered to You Automatically Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CELC News Today DCGO News Today VMD News Today PSNL News Today AIRS News Today LFMD News Today SERA News Today CORBF News Today QIPT News Today EUDA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDSX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodesix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
